Martinez-Montoro, Jose IgnacioPinzon-Martín, Jose LuisDamas-Fuentes, MiguelFernandez-Valero, AndreaTinahones, Francisco J2023-05-032023-05-032022-03-07Martínez-Montoro JI, Pinzón-Martín JL, Damas-Fuentes M, Fernández-Valero A, Tinahones FJ. Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report. Front Endocrinol (Lausanne). 2022 Apr 14;13:8388871664-2392http://hdl.handle.net/10668/20559Type A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, such as metformin and thiazolidinediones, and high doses of insulin. We report for the first time the results of the use of combination therapy with a glucagon-like peptide-1 receptor agonist and a sodium-glucose cotransporter 2 inhibitor for the treatment of diabetes in the context of type A IR syndrome.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Type A insulin resistance syndromediabetesglucagon-like peptide-1 receptor agonistinsulin resistancesodium-glucose cotransporter 2 inhibitorBenzhydryl compoundsDiabetes mellitusGlucagon-Like peptidesGlucosidesHumansInsulinInsulin resistanceresearch article35498407open accessCompuestos de bencidriloDiabetes mellitusGlucósidosInsulinaPéptidos similares al glucagónPéptidos similares al glucagónResistencia a la insulina10.3389/fendo.2022.838887PMC9046779https://www.frontiersin.org/articles/10.3389/fendo.2022.838887/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046779/pdf